{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:48:40Z","timestamp":1790153320558,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jpeds.2014.10.068","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T07:17:38Z","timestamp":1415085458000},"page":"985-991.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth"],"prefix":"10.1016","volume":"166","author":[{"given":"Yin-Hsiu","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni-Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-An","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuu-Jen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hui","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Yi","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2014.10.068_bib1","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.jpeds.2014.10.068_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2014.10.068_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2014.10.068_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2014.10.068_bib5","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpeds.2014.10.068_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2014.10.068_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jpeds.2014.10.068_bib8","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2014.10.068_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2014.10.068_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2014.10.068_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2014.10.068_bib12","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2014.10.068_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2014.10.068_bib14","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","article-title":"Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy","volume":"78","author":"Ebbink","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2014.10.068_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00455-009-9252-x","article-title":"Oropharyngeal dysphagia in infants and children with infantile Pompe disease","volume":"25","author":"Jones","year":"2010","journal-title":"Dysphagia"},{"key":"10.1016\/j.jpeds.2014.10.068_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1203\/01.pdr.0000233014.84318.4e","article-title":"Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy","volume":"60","author":"Chien","year":"2006","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jpeds.2014.10.068_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.jpeds.2014.10.068_bib18","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2014.10.068_bib19","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2014.10.068_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A","article-title":"Molecular genetic study of Pompe disease in Chinese patients in Taiwan","volume":"13","author":"Ko","year":"1999","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jpeds.2014.10.068_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cardfail.2011.07.011","article-title":"Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy","volume":"17","author":"Chen","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.jpeds.2014.10.068_bib22","series-title":"Peabody Developmental Motor Scales, 2nd Edition (PDMS-2)","author":"Folio","year":"2000"},{"key":"10.1016\/j.jpeds.2014.10.068_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1363849031000139298","article-title":"Development of a disease-specific disability instrument for Pompe disease","volume":"6","author":"Haley","year":"2003","journal-title":"Pediatr Rehabil"},{"key":"10.1016\/j.jpeds.2014.10.068_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2466\/pms.107.1.29-44","article-title":"Concurrent validity in Taiwan of the Comprehensive Developmental Inventory for Infants and Toddlers who were full-term infants","volume":"107","author":"Liao","year":"2008","journal-title":"Percept Mot Skills"},{"key":"10.1016\/j.jpeds.2014.10.068_bib25","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1016\/j.ridd.2013.06.037","article-title":"A randomized controlled trial of routines-based early intervention for children with or at risk for developmental delay","volume":"34","author":"Hwang","year":"2013","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.jpeds.2014.10.068_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2012.04.013","article-title":"Algorithm for Pompe disease newborn screening: results from the Taiwan screening program","volume":"106","author":"Chiang","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2014.10.068_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ymgme.2009.12.014","article-title":"Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program","volume":"99","author":"Labrousse","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2014.10.068_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ymgme.2010.08.001","article-title":"Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy","volume":"101","author":"Raben","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jpeds.2014.10.068_bib29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1525-0016(02)90716-1","article-title":"Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme","volume":"6","author":"Raben","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpeds.2014.10.068_bib30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/GIM.0b013e3181d2900e","article-title":"The angiotensin-converting enzyme insertion\/deletion polymorphism modifies the clinical outcome in patients with Pompe disease","volume":"12","author":"de Filippi","year":"2010","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2014.10.068_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1750-1172-8-90","article-title":"Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy","volume":"8","author":"Prater","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2014.10.068_bib32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jpeds.2014.10.068_bib33","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jpeds.2014.10.068_bib34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1750-1172-8-182","article-title":"Phenotypical variation within 22 families with Pompe disease","volume":"8","author":"Wens","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2014.10.068_bib35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00005072-197107000-00008","article-title":"Nervous system in Pompe's disease. Ultrastructure and biochemistry","volume":"30","author":"Gambetti","year":"1971","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jpeds.2014.10.068_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00687878","article-title":"Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle","volume":"23","author":"Martin","year":"1973","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.jpeds.2014.10.068_bib37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10545-010-9209-0","article-title":"CRIM-negative infantile Pompe disease: 42-month treatment outcome","volume":"33","author":"Rohrbach","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jpeds.2014.10.068_bib38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1044\/jshr.1202.246","article-title":"Differential diagnostic patterns of dysarthria","volume":"12","author":"Darley","year":"1969","journal-title":"J Speech Hear Res"},{"key":"10.1016\/j.jpeds.2014.10.068_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mus.24257","article-title":"Prominent vacuolation of the eyelid levator muscle in an early-treated child with infantile-onset Pompe disease","volume":"50","author":"Chien","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2014.10.068_bib40","first-page":"379","article-title":"Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings","volume":"27","author":"Teng","year":"2004","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.jpeds.2014.10.068_bib41","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.jpeds.2014.10.068_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"10.1016\/j.jpeds.2014.10.068_bib43","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002234761401035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002234761401035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T08:57:21Z","timestamp":1758358641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002234761401035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S002234761401035X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2014.10.068","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Prognosis of Patients with Infantile-Onset Pompe Disease Diagnosed by Newborn Screening and Treated since Birth","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2014.10.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}